- Details
- Joining Alicia Morgans is Mark Markowski to discuss the results of a phase Ib/II study of the oral agent sabizabulin, also known as VERU-111. There is an unmet need for additional therapies for men with metastatic castration-resistant prostate cancer (mCRPC). Dr. Markowski shares findings from this study presented at GU ASCO 2022 including recommended phase two dose, what they found in terms of th...
|
- Details
- In this discussion, Neal Shore joins Alicia Morgans in a conversation about a clinical trial for patients with mHSPC, the ARASEC trial. This study is designed to demonstrate how well darolutamide administered together with androgen deprivation therapy works in men with metastatic hormone-sensitive prostate cancer. Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic...
|
- Details
- Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director, Seattle...
|
- Details
- Alicia Morgans and Fred Saad discuss the ongoing ARANOTE trial, assessing darolutamide and androgen deprivation therapy (ADT), as compared to ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ARANOTE is an international, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Dr. Saad gives a background on the trial. Biographies: Fred Saad, MD, FRCS...
|
- Details
- In this UroToday discussion between Alicia Morgans and Mark Markowski, they discuss the results of a Phase 1b/2 study of sabizabulin, an androgen receptor transport disruptor, in men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent. Sabizabulin is an oral agent that inhibits microtubule assembly as well as disrupts androgen receptor trans...
|
- Details
- Alica Morgans is joined by Ronald Tutrone to provide an update on the clinical trial VERU 100. VERU‑100 is a novel, proprietary long-acting gonadotropin-releasing hormone (GnRH) antagonist peptide 3-month subcutaneous depot formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT). Biographies: Ronald Tutrone, MD, FACS, CPI, National Med...
|
- Details
- Alicia Morgans and Michael Morris, discuss the PSMAfore trial in progress. At the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial which examines the role of [177Lu]Lu-PSMA-617 in taxane-naïve patients with mCRPC. Dr. Morris reviews the radiographic progression-free survival (rPFS) data from the VISION trial and the complementary dat...
|
- Details
- Joining Alicia Morgans is Robert Dreicer highlighting a currently enrolling Phase III trial of sabizabulin, an oral cytoskeleton disruptor in mCRPC. The VERACITY trial s a blinded trial of 245 patients randomized to two to one drug, to the alternative ARI. Dr. Dreicer describes the rationale for the trial, the trial design, and the eligibility criteria. Biographies: Robert Dreicer, MD, MS, MACP, F...
|
- Details
- Alicia Morgans and Rahul Aggarwal, discuss the recent presentation on the phase 1b study of lutetium-177 combined with pembrolizumab. This phase I/II trial is evaluating the safety signals of the treatment combination. Biographies: Rahul Aggarwal, MD Assistant Professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Family Comprehensive Cancer Center Alicia Morgans, MD, MPH As...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the TALAPRO-1 study, an internationally conducted clinical trial that assesses the effectiveness of talazoparib in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with DNA repair alterations. The study is an open-label, phase II trial and includes patients with progressive mCRPC who have had at...
|
